NGL Fine-Chem Ltd.

₹3,040.4

16.9 (0.6%)

NGLFINE Share Price

Pharmaceuticals & Biotechnology

As on August 19, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,875 Cr

P/E Ratio39.03

Dividend Yield0.01 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	3,172.36	Bearish
10-DMA	3,300.84	Bearish
20-DMA	3,281.06	Bearish
50-DMA	3,161.49	Bearish
100-DMA	2,775.74	Bullish
200-DMA	2,241.1	Bullish

Historical Performance

1 Year

112.8%

3 Years

54.8%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	5,010	3,683	3,387	2,781	3,175
Total Expenditure	4,276	3,335	2,849	2,431	2,493
Other Income	147	86	141	55	107
Operating Profit	881	434	679	405	789
Interest	51	33	18	18	19
Depreciation	196	125	116	113	104
Profit Before Tax	634	277	544	274	666
Consolidated Net Profit	481	211	412	204	498
Adjusted EPS	78	34	67	33	81

Compounded Sales Growth

10 Years:26.7

5 Years:14.2

3 Years:12.5

TTM:6.3

Compounded Profit Growth

10 Years:19

5 Years:-3.2

3 Years:18.7

TTM:17.9

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:15.7

TTM:106.6

Return on Equity

10 Years:N/A

5 Years:80.7

3 Years:66.6

last year:77.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	31	31	31	31	31
Total Reserves	3,261	2,793	2,595	2,195	2,001
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	686	410	63	62	81
Other Current Liabilities	304	174	40	37	44
Short Term Borrowings	520	480	317	284	234
Total Liabilities	5,605	4,419	3,555	2,871	2,769
Capital Work in Progress	946	497	455	263	64
Long Term Loans & Advances	79	136	72	58	57
Currents Investments	392	597	536	395	287
Short Term Loans and Advances	188	47	211	150	212
Total Current Assets	2,890	2,339	2,127	1,627	1,735
Total Assets	5,605	4,419	3,555	2,871	2,769
Adjusted Book Value	533	457	425	360	329

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 39.03, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 15.3%, indicating sustained price appreciation.
The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹881 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹5010 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 2064507.4

No. of Shares: 679 (Approx)

Performance:106.5%

1064507.4

NIFTY Performance: -3.9%

1 day Top Gainers